Biomea Fusion Announces Proposed Public Offering of Securities

Core Viewpoint - Biomea Fusion, Inc. has initiated an underwritten public offering of its common stock and accompanying warrants, with a potential additional 15% of shares available for underwriters [1][2]. Group 1: Offering Details - The offering includes common stock, pre-funded warrants, and warrants to purchase common stock, all to be sold by Biomea [1]. - The expected closing date for the offering is around June 20, 2025, pending customary closing conditions [2]. - Jefferies is the sole book running manager for this public offering [2]. Group 2: Regulatory Information - The securities are being offered under an effective shelf registration statement on Form S-3, filed with the SEC on October 14, 2022, and declared effective on October 24, 2022 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available through Jefferies and the SEC's website [3]. Group 3: Company Overview - Biomea Fusion is a clinical-stage company focused on developing oral small molecules, icovamenib and BMF-650, aimed at improving the lives of patients with diabetes, obesity, and metabolic diseases [5].